GILD
NASDAQGilead Sciences Inc.
Price$146.82+0.91 (+0.63%)
01:30 PM07:45 PM
News · 26 weeks106+71%
2026-03-012026-08-23
Mix4190d
- Other16(39%)
- Insider16(39%)
- Earnings3(7%)
- SEC Filings3(7%)
- Analyst2(5%)
- M&A1(2%)
Latest news
25 items- PREuropean Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status– European Approval Received for Trodelvy plus Pembrolizumab in First-Line PD-L1-Positive Metastatic Triple-Negative Breast Cancer (TNBC) – – Approval Establishes Trodelvy as the First and Only Antibody-Drug Conjugate for the Treatment of First-Line Metastatic TNBC, Across PD-L1 Status – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and
- INSIDERDirector Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDEREVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- SECSEC Form S-3ASR filed by Gilead Sciences Inc.S-3ASR - GILEAD SCIENCES, INC. (0000882095) (Filer)
- SECSEC Form 10-Q filed by Gilead Sciences Inc.10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)
- PRCORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial ResultsProduct Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was $(6.75) Reflecting $(9.08) Per Share Acquired IPR&D and Tax Expenses Associated with Recent Acquisitions Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europe have been updated to $58 million for the three months ended June 30, 2026 (instead of $28 million). The updated release reads: GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Product Sales Excluding Vekl
- INSIDERChairman & CEO O'Day Daniel Patrick sold $1,954,694 worth of shares (15,000 units at $130.31) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 592,133 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- SECGilead Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
- PRGilead Sciences Announces Second Quarter 2026 Financial ResultsProduct Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was $(6.75) Reflecting $(9.08) Per Share Acquired IPR&D and Tax Expenses Associated with Recent Acquisitions Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the second quarter 2026. "Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi. HIV sales grew 12%, reflecting continued strength in treatment and the rapid expansion of our PrEP business,
- SECSEC Form 13F-HR filed by Gilead Sciences Inc.13F-HR - GILEAD SCIENCES, INC. (0000882095) (Filer)
- FDAFDA Approval for VEKLURY issued to GILEAD SCIENCES INCSubmission status for GILEAD SCIENCES INC's drug VEKLURY (SUPPL-33) with active ingredient REMDESIVIR has changed to 'Approval' on 07/29/2026. Application Category: NDA, Application Number: 214787, Application Classification: Labeling
- PRCHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer– A Second Approval in First-Line Would Establish Trodelvy as a Backbone Therapy Across PD-L1 Status in the European Union – – ASCENT-04/KEYNOTE-D19 Demonstrated a Highly Statistically Significant and Clinically Meaningful Reduction in the Risk of Disease Progression or Death – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab), for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative
- PRGilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2026 financial results and provide a business update.A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.About Gilead SciencesGilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is
- ANALYSTGilead Sciences downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Gilead Sciences from Outperform to Market Perform and set a new price target of $127.00
- INSIDERChief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- ANALYSTGilead Sciences upgraded by HSBC Securities with a new price targetHSBC Securities upgraded Gilead Sciences from Hold to Buy and set a new price target of $155.00
- INSIDERChairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- PRU.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer– Trodelvy is a New Backbone Therapy and the Only Approved ADC in First-Line mTNBC Across PD-L1 Status – – Approval Builds on Trodelvy’s Leadership in Second-Line mTNBC and Pre-Treated HR+/HER2- Metastatic Breast Cancer with More than 75,000 Patients Treated Globally – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). Trodelvy is now approved in first-line mTNBC either as a single agent fo
- PRNext-Generation DNA Repair Inhibitors Could Capture Billions in Emerging MarketAUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response ("DDR") inhibitors, a category of drugs that work by blocking cancer cells' capacity to fix their own damaged DNA, are growing well beyond the poly ADP ribose polymerase ("PARP") inhibitor that first defined the category. DDR-inhibiting therapies generated an estimated $7 billion-plus in worldwide sales in 2025, and the wider oncology, diagnostics and precision medicine markets are expected to approach about $750 billion by 2030. A fresh wave of inhibitor classes is now taking shape as the next major opportunity.
- PREuropean Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors–Trodelvy is the First Antibody-Drug Conjugate (ADC) and First New Treatment Option in 20 Years in Europe for Certain Patients with First-Line Metastatic Triple-Negative Breast Cancer – – Authorization Based on ASCENT-03 Study in Which Trodelvy Demonstrated Highly Statistically Significant and Clinically Meaningful Progression-Free Survival (PFS) Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC
- INSIDERChief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
GILD FAQ
8 questionsWhat does Gilead Sciences Inc. do?
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus...Where does GILD stock trade?
Gilead Sciences Inc. (GILD) is listed on NASDAQ.What sector and industry is GILD in?
Gilead Sciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Gilead Sciences Inc. go public?
Gilead Sciences Inc. (GILD) completed its IPO in 1992.Does GILD pay a dividend?
Yes. GILD's next ex-dividend date is 2026-09-15 with a declared cash dividend of $0.82 per share, payable 2026-09-29.What are analysts saying about GILD?
Gilead Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Market Perform on 2026-07-21.What companies are similar to GILD?
Notable peers in the same industry include ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), PFE (Pfizer Inc.), BMY (Bristol-Myers Squibb Company). Compare GILD side-by-side with any of them on Quantisnow.How can I track GILD on Quantisnow?
Quantisnow aggregates Gilead Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GILD to receive live email and push alerts on every new disclosure.